The development, evaluation, performance and validation of micro-PCR and extractor for the quantification of HIV-1 &-2 RNA

Author:

Prakash Shyam1,Aasarey Ram1,Priyatma Priyatma1,Sharma Meenakshi1,Khan Shahid1,Medha Medha1

Affiliation:

1. All India Institute of Medical Sciences, Ansari Nagar, New Delhi

Abstract

Abstract HIV infection has been a global public health threat and reported ~ 40 million deaths. AIDS is caused by the retrovirus, HIV-1, which is transmitted via body fluids and secretions during the time AIDS in HIV-2 infection is twice as compared to an HIV-1. Q-PCR is the only available method that requires trained personnel and lab infrastructure. Micro-PCR is a portable Q-PCR developed by Bigtec Bangalore, India, which is simple, accurate, fast, and operationalized in remote places where diagnostic services are not easily accessible in the country. This micro-PCR can determine simultaneously HIV-1 and HIV-2 viral load using a TruePrep™ extractor device for RNA isolation. 5.0 ml blood samples were collected at the blood collection centre at AIIMS, New Delhi, India. Samples were screened for serology and a comparison of HIV-1/-2 RNA was done between QPCR and micro-PCR in the samples. The micro-PCR assay of HIV-RNA has compared well with those from real-time PCR (r = 0.99, p > 0.002). Micro-PCR has good inter and intra-assay reproducibility over a wide dynamic range (1.0x102 to 1.0x108 IU/ml). The linear dynamic range was 102 to 108. The clinical and analytical specificity of the assay was comparable i.e., 100%. Intra-assay and inter-assay coefficient of variation ranged from 1.17–3.15% and from 0.02–0.46% respectively. This micro-PCR is reliable, accurate and reproducible for early HIV-1 and HIV-2 viral load detection. This can easily be used in the field and in remote places where quantification of both HIV-1/-2 is not reachable.

Publisher

Research Square Platform LLC

Reference29 articles.

1. WHO report, “HIV Global Situtations and Trends,” 2023. https://www.who.int/data/gho/data/themes/hiv-aids

2. 2023 UNAIDS/WHO estimates, “HIV data and statistics,” 2023. https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/strategic-information/hiv-data-and-statistics

3. S. ‘Assessment of P. T. by B. German Advisory Committee Blood (Arbeitskreis Blut), “Human Immunodeficiency Virus (HIV).,” Transfusion medicine and hemotherapy: offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, vol. 43, no. 3. Switzerland, pp. 203–222, May 2016. doi: 10.1159/000445852.

4. WHO, “HIV and AIDS,” 2023. https://www.who.int/news-room/fact-sheets/detail/hiv-aids

5. Single-copy quantification of HIV-1 in clinical samples;Wiegand A;Methods Mol. Biol.,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3